CY1115866T1 - Τριαζολοπυριμιδινες - Google Patents

Τριαζολοπυριμιδινες

Info

Publication number
CY1115866T1
CY1115866T1 CY20141100970T CY141100970T CY1115866T1 CY 1115866 T1 CY1115866 T1 CY 1115866T1 CY 20141100970 T CY20141100970 T CY 20141100970T CY 141100970 T CY141100970 T CY 141100970T CY 1115866 T1 CY1115866 T1 CY 1115866T1
Authority
CY
Cyprus
Prior art keywords
compounds
formula
triazolopyrimidines
simeon
tkk
Prior art date
Application number
CY20141100970T
Other languages
English (en)
Inventor
Volker Schulze
Marcus Koppitz
Dirk Kosemund
Hartmut Schirok
Benjamin Bader
Philip Lienau
Antje Margret Wengner
Hans Briem
Simon Holton
Gerhard Siemeister
Stefan Prechtl
Ulf Bömer
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1115866T1 publication Critical patent/CY1115866T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

Η παρούσα εφεύρεση σχετίζεται με ενώσεις τριαζολοπυριδίνης του γενικού τύπου (I) που είναι αναστολείς της κινάσης Μονοπολικής Ατράκτου (Monopolar Spindle) 1(Mps-1 ή ΤΤΚ): Τύπος (I), στον οποίον R1, R2, R3, R4 και R5 είναι, όπως περιγράφονται στην περιγραφή και τις αξιώσεις, με μεθόδους παρασκευής των εν λόγω ενώσεων, με φαρμακευτικές συνθέσεις και συνδυασμούς που περιέχουν τις εν λόγω ενώσεις, με τη χρήση των εν λόγω ενώσεων για την κατασκευή μιας φαρμακευτικής σύνθεσης για την θεραπεία ή την προφύλαξη από υπερπλαστικές νόσους, καθώς και με ενδιάμεσες ενώσεις, χρήσιμες στην παρασκευή των εν λόγω ενώσεων.
CY20141100970T 2009-11-30 2014-11-21 Τριαζολοπυριμιδινες CY1115866T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075535A EP2343297A1 (en) 2009-11-30 2009-11-30 Triazolopyridines
EP10787274.9A EP2507235B1 (en) 2009-11-30 2010-11-17 Triazolopyrimidines

Publications (1)

Publication Number Publication Date
CY1115866T1 true CY1115866T1 (el) 2017-01-25

Family

ID=42028156

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100970T CY1115866T1 (el) 2009-11-30 2014-11-21 Τριαζολοπυριμιδινες

Country Status (36)

Country Link
US (1) US9676766B2 (el)
EP (2) EP2343297A1 (el)
JP (1) JP5805653B2 (el)
KR (1) KR20120115290A (el)
CN (1) CN102762557B (el)
AR (1) AR079166A1 (el)
AU (1) AU2010324155B2 (el)
BR (1) BR112012012906A2 (el)
CA (1) CA2781915A1 (el)
CL (1) CL2012001391A1 (el)
CR (1) CR20120295A (el)
CU (1) CU24100B1 (el)
CY (1) CY1115866T1 (el)
DK (1) DK2507235T3 (el)
DO (1) DOP2012000150A (el)
EA (1) EA022353B1 (el)
EC (1) ECSP12011935A (el)
ES (1) ES2525069T3 (el)
GT (1) GT201200165A (el)
HK (1) HK1178153A1 (el)
HN (1) HN2012001162A (el)
HR (1) HRP20141093T1 (el)
IL (1) IL219750A (el)
MA (1) MA33768B1 (el)
MX (1) MX2012006252A (el)
MY (1) MY160325A (el)
NZ (1) NZ600229A (el)
PE (1) PE20121509A1 (el)
PL (1) PL2507235T3 (el)
PT (1) PT2507235E (el)
RS (1) RS53670B1 (el)
SI (1) SI2507235T1 (el)
TN (1) TN2012000265A1 (el)
UA (1) UA108486C2 (el)
WO (1) WO2011063908A1 (el)
ZA (1) ZA201203806B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2013545776A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080234A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821837A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103403006B (zh) 2010-12-17 2015-11-25 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
WO2012130905A1 (en) 2011-03-31 2012-10-04 Bayer Pharma Aktiengesellschaft Substituted benzimidazoles
CA2832310A1 (en) 2011-04-06 2012-10-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
MA35049B1 (fr) * 2011-04-21 2014-04-03 Bayer Ip Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
PE20150354A1 (es) * 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014118186A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EP3007692A1 (en) 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP2980088A1 (en) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP3129374B1 (en) 2014-04-07 2018-12-19 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
EP2977375A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977377A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977376A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
KR101686411B1 (ko) * 2015-12-28 2016-12-14 한국원자력의학원 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
EP3492500B1 (en) 2017-12-01 2023-09-20 Daikin Industries, Ltd. Use of a crosslinked product of a fluorine-containing amorphous elastomer
US20230391768A2 (en) * 2018-11-07 2023-12-07 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US20240123043A1 (en) * 2021-02-22 2024-04-18 Orgenesis Inc. Pharmaceutical compositions comprising ranpirnase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2005030121A2 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
KR20100049073A (ko) * 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011504900A (ja) 2007-11-27 2011-02-17 セルゾーム リミティッド Ｐｉ３ｋ阻害剤としてのアミノトリアゾール
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
CN102317288A (zh) 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
EP2424537B1 (en) 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
CA2784765A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators

Also Published As

Publication number Publication date
RS53670B1 (en) 2015-04-30
EA022353B1 (ru) 2015-12-30
UA108486C2 (en) 2015-05-12
IL219750A0 (en) 2012-07-31
HK1178153A1 (zh) 2013-09-06
CN102762557B (zh) 2015-10-07
BR112012012906A2 (pt) 2017-03-01
NZ600229A (en) 2014-06-27
MX2012006252A (es) 2012-09-07
CU20120084A7 (es) 2012-10-15
US20120328610A1 (en) 2012-12-27
DK2507235T3 (en) 2014-12-15
ES2525069T3 (es) 2014-12-17
EA201200794A1 (ru) 2013-03-29
MY160325A (en) 2017-02-28
CN102762557A (zh) 2012-10-31
DOP2012000150A (es) 2012-09-30
EP2507235A1 (en) 2012-10-10
HRP20141093T1 (hr) 2015-01-16
PE20121509A1 (es) 2012-11-18
HN2012001162A (es) 2015-08-10
CA2781915A1 (en) 2011-06-03
CR20120295A (es) 2012-07-30
WO2011063908A1 (en) 2011-06-03
JP2013512264A (ja) 2013-04-11
US9676766B2 (en) 2017-06-13
SI2507235T1 (sl) 2015-01-30
AR079166A1 (es) 2011-12-28
EP2507235B1 (en) 2014-10-22
PT2507235E (pt) 2014-12-11
TN2012000265A1 (en) 2013-12-12
ZA201203806B (en) 2013-07-31
EP2343297A1 (en) 2011-07-13
KR20120115290A (ko) 2012-10-17
PL2507235T3 (pl) 2015-03-31
MA33768B1 (fr) 2012-11-01
IL219750A (en) 2014-02-27
AU2010324155A1 (en) 2012-06-07
ECSP12011935A (es) 2012-07-31
CU24100B1 (es) 2015-07-30
CL2012001391A1 (es) 2012-10-26
AU2010324155B2 (en) 2015-10-01
JP5805653B2 (ja) 2015-11-04
GT201200165A (es) 2014-01-03

Similar Documents

Publication Publication Date Title
CY1115866T1 (el) Τριαζολοπυριμιδινες
CY1116958T1 (el) Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις
CY1117352T1 (el) Υποκατεστημενες ιμιδαζοπυριδαζiνες
CY1116439T1 (el) Τριαζολοπυριδινες
CY1120673T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
BR112012029647A2 (pt) novos derivados de pirimidinas
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
UY31838A (es) Derivados de quinoxalin- y quinolin-carboxamida
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
TN2010000131A1 (en) Polo-like kinase inhibitors
CY1113573T1 (el) Selurampanel
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY32077A (es) Inhibidores de quinasa tipo polo
BR112012014058A8 (pt) Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina